


## REMARKS

### The Rejection Under 35 USC § 102

Applicants respectfully submit that the rejection is erroneous.

Xiang et al (WO 98/31227) is not anticipatory. Neither the exemplified compound (page 18, line 5), nor the generic formula I, are within the scope of the claims.

Xiang et al teaches compounds of the following formula




where

X is O or NR<sub>5</sub>;

The group "-X(CH<sub>2</sub>)<sub>n</sub>R<sub>4</sub>" of Xiang et al corresponds to group "R<sup>2</sup>" of the present application.

The situation in the pending claims is as follows



R<sup>2</sup> denotes (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>Ar, cycloalkyl having 3 to 7 C atoms or CF<sub>3</sub>.

Since R<sup>2</sup> of the present claims can never be "-O(CH<sub>2</sub>)<sub>n</sub>R<sub>4</sub>" or "-NR<sub>5</sub>(CH<sub>2</sub>)<sub>n</sub>R<sub>4</sub>," the claimed matter is not anticipated by Xiang et al.

The same holds true for the exemplified compound (page 18, line 5), which is an example of a "-O(CH<sub>2</sub>)<sub>2</sub>R<sub>4</sub>"-compound (with R<sub>4</sub> being 2-morpholin) (see "2-morpholin-4-ylethoxy" in

## 5-(2-morpholin-4-ylethoxy)-1-(4-(4-carboxyphenyl)phenyl)pyrazole-4-carboxylic acid

Accordingly, the compounds exemplified in Xiang et al are perfectly in line with the scope of the generic formula I in Xiang et al., and as such, do not anticipate the claims herein.

Reconsideration is respectfully and courteously requested.

### **Withdrawn Claims**

Applicants continue to respectfully disagree with the restriction.

The Patent Office has not established that it would pose a serious burden on the Examiner to search all the groups. No further, or only a minimal, search would be necessary to allow the remaining groups once the elected claims are allowed.

Regarding the Election of Species Requirement, applicants remind the Examiner in accordance with M.P.E.P. 803.02, that should no prior art be found which renders the invention of the elected species unpatentable, the search of the remainder of the generic claim(s) should be continued in the same application. Since the decisions in *In re Weber*, 580 F.2d 455, 198 USPQ 328 (CCPA 1978) and *In re Haas*, 580 F.2d 461, 198 USPQ 334 (CCPA 1978), it is improper for the Office to refuse to examine that which applicants regard as their invention, unless the subject matter in a claim lacks unity of invention. See MPEP 803.02 in accord.

Additionally, applicants bring the attention of the Examiner to MPEP § 821.04, Rejoinder, which states that “if the elected invention is directed to the product and the claims directed to the product are subsequently found patentable, process claims [both process of making and using] which either depend from or include all the limitations of the allowable product will be rejoined.” Accordingly, the rejoinder of the withdrawn method claims is respectfully requested at the proper time in accord with the rejoinder provisions of the MPEP.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

/Csaba Henter/

---

Csaba Henter, Reg. No. 50,908  
Attorney for Applicants

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Boulevard, Suite 1400  
Arlington, VA 22201  
Direct Dial: 703-812-5331  
Facsimile: 703-243-6410  
Attorney Docket No.:MERCK-3074

Date: January 14, 2010

K:\Merck\3000 - 3999\3074\Reply Sept 09 R.doc